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The Department of Obstetrics, Gynecology, and Reproductive Sciences at the Yale School
of Medicine hosted a daylong continuing medical education (CME†) symposium titled
“Health and Medicine for Women: A Multidisciplinary, Evidence-Based Review of Mid-Life
Health Concerns” in September 2010. A number of speakers discussed current research on
hormone replacement therapy (HRT) and re-evaluated the results of the Women’s Health
Initiative (WHI), a landmark, randomized, placebo-controlled trial that still sparks debate al-
most a decade after its conclusion. This article summarizes this discussion and highlights
directions for future study.
Since its approval by the Food and
Drug Administration (FDA) in 1942, estro-
gen has been used to alleviate the symp-
toms  of  menopause,  a  period  when
endogenous estrogen production declines.
For many years, it was widely believed that
estrogen replacement also could prevent
disease  and  extend  life.  In  1991,  the
Women's Health Initiative (WHI), a land-
mark, randomized, placebo-controlled trial,
was initiated to test the ability of hormone
replacement therapy (HRT) — an umbrella
term for both estrogen-only and estrogen-
progestin treatments — to prevent heart
disease  and  breast  cancer  in  post-
menopausal women.
Despite years of promotion and popu-
larity, HRT usage fell dramatically after the
conclusion of the WHI.
In 2002, the WHI was terminated early
due to trends in the data showing that HRT
was actually associated with increasingrates
of cardiovascular disease [1] and breast can-
cer [2] in postmenopausal women. However,
HRT remains the most effective treatment
available today for the disruptive symptoms
of menopause. Given the size of the aging
population and the increasing number of
To whom all correspondence should be addressed: Lydia Shook, Yale University School of
Medicine, New Haven, CT; E-mail: lydia.shook@yale.edu.
†Abbreviations: CME, continuing medical education; HRT, hormone replacement therapy;
WHI, Women’s Health Initiative; KEEPS, Kronos Early Estrogen Prevention Study; FDA,
Food and Drug Administration; HERS, Heart and Estrogen Replacement Study; CHD, coro-
nary heart disease; TSECs, tissue selective estrogen complexes; SERM, selective estrogen
receptor  modulator; ACOG, American  Congress  of  Obstetricians  and  Gynecologists.1Note that recent findings from the WHI [9] were not known to the speaker at the time of this symposium.
See discussion on the new study later in this article.
Shook: Update on hormone replacement therapy 40
postmenopausal women in the United States,
interest in the therapeutic potential of estro-
gen has continued to spark new efforts to un-
derstand the long-term health consequences
of this powerful drug. In the continuing med-
ical education (CME) symposium in Sep-
tember 2010 at Yale School of Medicine titled
“Health and Medicine for Women: A Multi-
disciplinary, Evidence-Based Review of Mid-
Life Health Concerns,” a number of speakers
revisited the results of the WHI in light of re-
cent evidence.
In his presentation, “Heart Disease in
Women: Is it Different than in Men?” Dr.
Jeffrey R. Bender, Robert I. Levy Professor
of Preventive Cardiology at Yale School of
Medicine, discussed the effects of HRT on
cardiovascular health. He suggested the pos-
sibility that the conclusions of the WHI may
have been exaggerated. The WHI enrolled
women who were on average 12 years past
menopause, with a mean age of 63. He ar-
gued that significant vascular disease may
have already been present in the study pop-
ulation at the time of therapy initiation and
that estrogen may not reverse established
pathological changes. In support of this idea,
an animal study showed that primates given
estrogen  replacement  immediately  after
ovariectomy showed a 70 percent reduction
in coronary artery atherosclerosis compared
to placebo, while those given estrogen after
a delay period found no benefit [3]. Further-
more, a subset analysis of women aged 50
to 59 and enrolled in the WHI found a sig-
nificant reduction in cardiovascular disease
[4]. This evidence suggests that if given in
low doses early in the menopausal transi-
tion, estrogen may be cardioprotective as
was  once  believed. The  ongoing  Kronos
Early Estrogen Prevention Study (KEEPS)
investigates estrogen and intermittent prog-
estin on atherosclerosis in the younger pop-
ulation.  Its  pending  results  may  provide
insight into this issue.
In  his  presentation,  “Update  on
Menopausal Hormone Therapy,” Dr. Hugh
Taylor, Section Chief of Obstetrics and Gy-
necology, echoed Dr. Bender. He presented
evidence from the Heart and Estrogen Re-
placement Study (HERS). While HRT ap-
peared to increase the risk of primary CHD
events  in  the  first  year  of  treatment  in
women with established vascular disease, it
actually decreased risk in subsequent years
[5]. He emphasized that the women who re-
ceived estrogen therapy without progestin
showed a reduced incidence of CHD events,
a conclusion corroborated by experiments in
nonhuman primates [6].
Dr. Taylor also suggested that limita-
tions of the WHI should be carefully con-
sidered when interpreting the data on breast
cancer.1 WHI results did not evaluate mor-
tality or the causal link between HRT and
breast cancer. Using data on the detection
rates of different stages and types of breast
cancer, he suggested an alternative hypoth-
esis. Combination therapy may stimulate the
growth of previously existing, subclinical
cancers, thereby increasing the incidence of
detectable cancer  compared  to  placebo.
Meanwhile, the estrogen-only arm of the
WHI trial showed lower incidence of breast
cancer than placebo, with the lowest inci-
dence in the subset of women who were
highly compliant with the therapy [7]. Es-
trogen-only HRT may not have the same risk
profile as combination therapy, a conclusion
supported by a recent cohort study [8]. Es-
trogen-only HRT could, therefore, be a safe
option  for  symptom  management  in  a
younger woman with prior hysterectomy
(estrogen without progestin has a stimula-
tory effect on the uterine lining, which can
lead to endometrial cancer), especially if her
overall risk for breast cancer is low.
During the review of this article, an 11-
year follow-up study of the WHI was pub-
lished  [9].  It  demonstrated  a  two-fold
relative increase in mortality due to breast
cancer in women who had taken combina-
tion therapy compared to placebo. The dif-
ference in absolute number of deaths was
real but small (2.6 vs. 1.3 deaths per 10,000
women per year). Therefore, combinationShook: Update on hormone replacement therapy 41
HRT is associated with an increased risk of
both breast cancer detection and mortality.
In an interview with the Washington Post,
Dr. Taylor stated that these results necessi-
tate a “paradigm shift” in how we think
about HRT and breast cancer [10].
Finally, in her presentation, “Depres-
sion, Anxiety, and Cognition in Mid-Life,”
Dr. Ariadna Forray in the Department of
Psychiatry at Yale School of Medicine dis-
cussed ways in which estrogen therapy may
have psychological benefits in women en-
tering menopause. Estrogen affects multiple
systems involved in mood, learning, and
memory. When given transdermally, 17ʲ-
estradiol has been shown to treat depression
in perimenopausal women [11] and acceler-
ate the response to other antidepressants
[12]. However, benefits of HRT on cogni-
tion  and  memory  seem  to  apply  only  to
women early in the menopausal transition
[13]. This stands in contrast to the WHI,
which showed an increased risk of dementia
in  its  study  population  of  mostly  post-
menopausal women [14]. Dr. Forray em-
phasized that hormone-based treatment of
the  cognitive  and  mood  disturbances  of
menopause  may  be  beneficial  only  in
younger women. The risks and benefits of
HRT on the brain remain a focus of investi-
gation.
In light of the WHI results, the American
Congress of Obstetricians and Gynecologists
(ACOG) recommends using the lowest ef-
fective dose of HRT for the shortest possible
time to treat menopausal symptoms. How-
ever, questions about the long-term health
consequences of HRT remain. The women in
the WHI were older and taking higher doses
of estrogen than women using HRT today. In
addition, a number of other hormonal options
are available, yet their comparative risks and
benefits are unknown. These include differ-
ent types of hormones — conjugated and syn-
thetic estrogens, phytoestrogens, synthetic
progestin, and natural progesterone — and
modes of delivery — oral tablets, transder-
mal patches, local creams, and intrauterine
devices. Without further study, deciding on
the best treatment plan will continue to in-
volve an amount of guesswork.
Development  of  new  compounds  will
also help advance HRT. Efforts to develop tis-
sue-selective estrogen complexes (TSECs),
which combine estrogen with a selective es-
trogen receptor modulator (SERM) like ta-
moxifen, are currently under way. TSECs are
designed to deliver estrogen while blocking its
dangerous growth-promoting effects on tissues
such as the breast or endometrium. HRT will
remain the subject of debate and research as
long as estrogen remains the most effective
agent for treating menopausal symptoms.
REfEREnCES
1. Manson JE, et al. Estrogen plus progestin and
the risk of coronary heart disease. N Engl J
Med. 2003;349(6):523-34.
2. Chlebowski RT, et al. Influence of estrogen
plus progestin on breast cancer and mam-
mography  in  healthy  postmenopausal
women: the Women’s Health Initiative Ran-
domized Trial. JAMA. 2003;289(24):3243-
53.
3. Mikkola TS, Clarkson TB. Estrogen replace-
ment therapy, atherosclerosis, and vascular
function. Cardiovasc Res. 2002;53(3):605-
19.
4. Hsia J, et al. Conjugated equine estrogens and
coronary heart disease: the Women’s Health
Initiative. Arch Intern Med. 2006;166(3):357-
65.
5. Hulley S, et al. Randomized trial of estrogen
plus progestin for secondary prevention of
coronary heart disease in postmenopausal
women. Heart and Estrogen/progestin Re-
placement Study (HERS) Research Group.
JAMA. 1998;280(7):605-13.
6. Clarkson TB, et al. A comparison of tibolone
and conjugated equine estrogens effects on
coronary artery atherosclerosis and bone den-
sity of postmenopausal monkeys. J Clin En-
docrinol Metab. 2001;86(11):5396-404.
7. Stefanick ML, et al. Effects of conjugated
equine estrogens on breast cancer and mam-
mography  screening  in  postmenopausal
women  with  hysterectomy.  JAMA.
2006;295(14):1647-57.
8. Fournier A, et al. Unequal risks for breast can-
cer associated with different hormone eplace-
ment therapies: results from the E3N cohort
study.  Breast  Cancer  Res  Treat.
2008;107(1):103-11.
9. Chlebowski RT, et al. Estrogen Plus Prog-
estin and Breast Cancer Incidence and Mor-
tality in Postmenopausal Women. JAMA.
2010;304(15):1684-92.
10. Stein R. Hormones also raise death risk of cancer.
The Washington Post. 20 Oct. 2010. Available from:
http://www.washingtonpost.com/wp-dyn/con-
tent/article/2010/10/19/AR2010101907522.html.11. Soares CN, et al. Efficacy of estradiol for the
treatment  of  depressive  disorders  in  peri-
menopausal  women:  a  double-blind,  ran-
domized, placebo-controlled trial. Arch Gen
Psychiatry. 2001;58(6):529-34.
12. Rasgon NL, et al. Estrogen and response to
sertraline in postmenopausal women with
major depressive disorder: a pilot study. J
Psychiatr Res. 2007;41(3-4):338-43. 
13. Joffe H, et al. Estrogen therapy selectively en-
hances prefrontal cognitive processes: a ran-
domized, double-blind, placebo-controlled
study with functional magnetic resonance im-
aging in perimenopausal and recently post-
menopausal  women.  Menopause.
2006;13(3):411-22.
14. Shumaker SA, et al. Conjugated equine es-
trogens and incidence of probable dementia
and  mild  cognitive  impairment  in  post-
menopausal women: Women’s Health Initia-
tive  Memory  Study.  JAMA.
2004;291(24):2947-58.
42 Shook: Update on hormone replacement therapy